drug development · Asia

Chinese AI-discovered drug candidates reach regulatory and development milestones

Oct 12, 2026 · Issue 11 · 1 source, 2 articles

Chipscreen Biosciences' AML candidate CS43158, developed on an AI-supported platform, has received IND approval from China's NMPA. Hankang Pharmaceutical's AI-driven small-molecule program has also reached a key milestone.

Who is affected and how

pharmaceuticals: AI-discovered candidates from Chinese companies are already entering the stage of clinical trial authorisation.

Research and pharma

Sources

Hankang Pharmaceutical Reaches Key Milestone in AI-Driven Small Molecule Discovery Program for Oncology and Autoimmune Diseases - BioSpacebiospace.com · Oct 12, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.